Loading...
XNAS
EVO
Market cap985mUSD
Jul 09, Last price  
2.84USD
1D
2.16%
1Q
7.98%
Jan 2017
-27.04%
Name

Evotec SE

Chart & Performance

D1W1MN
XNAS:EVO chart
P/E
—
P/S
0.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.92%
Rev. gr., 5y
8.62%
Revenues
757m
-4.98%
67,354,00032,885,00039,613,00042,683,00055,262,00080,128,00087,265,00085,938,00089,496,000127,677,000164,507,000257,630,000375,405,000446,437,000500,924,000618,034,000751,448,000781,426,000796,967,000757,258,040
Net income
-99m
L-49.29%
-32,468,000-11,156,000-78,287,000-45,497,0003,260,0006,749,0002,478,000-25,433,000-6,978,00016,516,00027,530,00024,257,00084,172,00038,156,0006,278,000215,510,000-175,655,000-83,913,000-196,078,000-99,431,462
CFO
-9m
L
-9,225,000-31,672,000-41,278,000-21,853,000899,00010,146,00011,957,0006,657,000-3,797,00015,651,00067,360,00010,828,000156,240,00042,216,00044,721,000122,237,000205,811,00036,439,00018,220,000-9,064,546
Dividend
Jan 11, 20190.2888 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
URL
https://www.evotec.com/
IPO date
Oct 11, 1999
Employees
5,067
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT